诉讼案件 - 波默朗茨律师事务所宣布重新开放针对Spectrum Pharmaceuticals投资者的证券集体诉讼首席原告任命程序 [1] - 诉讼涉及Spectrum及其部分高管是否从事证券欺诈或其他非法商业行为 [2] - 投资者需在2025年9月24日前向法院申请成为首席原告 [2] 公司背景 - Spectrum是一家专注于肿瘤治疗的生物制药公司 [4] - 诉讼指控Spectrum就其Pinnacle研究向投资者作出虚假或误导性陈述 [4] - 争议涉及poziotinib药物的临床试验 该药物用于治疗特定肺癌患者 [4] 律师事务所 - 波默朗茨律师事务所在公司 证券和反垄断集体诉讼领域处于领先地位 [5] - 该事务所已为集体诉讼成员追回多笔数百万美元的损害赔偿 [5]

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, all datesinclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sar ...

Edesa Biotech (EDSA 1.44%), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, released its fiscal third quarter results on August 8, 2025, covering the period ended June 30, 2025. The company reported a GAAP EPS loss of $(0.25), outperforming the $(0.26) consensus estimate by $0.01, or 3.8% (GAAP). Revenue (GAAP) remained at $0, matching expectations and consistent with its pre-commercial status. Operating expenses (GAAP) held steady ye ...

业务进展 - 公司推进EB06（抗CXCL10单克隆抗体）的制造相关活动以支持美国监管机构批准其用于中重度非节段性白癜风的II期研究 [2] - 预计将于2025年底前向FDA提交EB06的IND申请制造数据 [2] - EB06具有良好安全性特征并能同时靶向影响皮损和非皮损皮肤的免疫机制 可能成为白癜风患者尤其是体表面积受累超过10%患者的优选治疗方案 [3] - 公司将运营重点转向EB06的监管准备和药物制造工作 旨在快速进入临床测试阶段 [4] 财务表现 - 2025年第二季度运营支出190万美元 与去年同期持平 [5] - 2025年第二季度其他收入下降11万美元至15.4万美元 主要由于加拿大政府战略创新基金报销资金和利息收入减少 [5] - 2025年第二季度净亏损170万美元（每股0.25美元） 去年同期净亏损170万美元（每股0.52美元） [6] - 2025年前九个月运营支出下降60万美元至540万美元 [7] - 2025年前九个月研发支出下降40万美元至240万美元 主要因EB05外部研究费用减少 部分被EB06相关费用增加抵消 [7] - 2025年前九个月净亏损500万美元（每股0.95美元） 去年同期净亏损520万美元（每股1.64美元） [10] 资金状况 - 截至2025年6月30日 公司持有现金及等价物1240万美元 营运资金1210万美元 [11] 公司概况 - 临床阶段生物制药公司 专注于炎症和免疫相关疾病治疗 [13] - 皮肤病学领域开发EB06（白癜风）和EB01（1% daniluromer乳膏 用于过敏性接触性皮炎） [13] - 呼吸系统领域开发EB05（paridiprubart）用于急性呼吸窘迫综合征 获加拿大政府两项资助 [13] 管理层活动 - 管理层将参加2025年8月Canaccord Genuity第45届年度增长会议和9月H.C. Wainwright第27届全球投资会议 [12]

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, Augus ...

PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. The Reverse Stock Split will become effective on August 8, 2025, at 5:00 p.m., Eastern Daylight Time (the "Effective Time") and the Common Stock is expected to begin trading on OCTQB Market of the OTC Markets on a Reverse Stock Split-adjusted basis on August 11, 2025 at market open. The Company's ticker symbol on the OTCQB ...

Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly’s Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage bio ...

机构持股情况 - 截至2025年3月31日，机构对Tevogen普通股的持股量较2024年12月31日增长60%，其中Vanguard和BlackRock合计增持151% [2] - 在51家持有Tevogen股票的机构投资经理中，73%选择增持或维持仓位，且仅1家机构与去年同期（2024年3月31日）持仓重合，显示新投资者大量涌入 [2] 公司发展动态 - Tevogen近期在AI领域取得进展，包括新专利活动以及与微软、Databricks的合作 [3] - 公司计划建立自有的GMP细胞制造设施，以推动针对癌症和传染病的靶向疗法开发 [3] 管理层观点 - 投资者关系主管Tapan Shah指出，机构持股增长反映市场对公司基本面和长期增长潜力的信心，强调机构投资者数量增加是积极信号 [3] 数据披露计划 - 公司将在下一个SEC报告期后再次更新机构持股情况 [3]

AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX). To hear the NetworkNewsAudio version, visit https://nnw.fm/Tflrp To read the original editorial, visit https://nnw.fm/JoDGY Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primaril ...